Summer School in Translational Cancer Research, October 8 – 14, 2023, Portugal
The CCE Summer School in Translational Cancer Research is intended to provide an in-depth training of scientists and clinicians to gain a cross-disciplinary knowledge of areas of the entire cancer research continuum.
The Summer School covers a broad spectrum of topics ranging from preclinical and clinical research to the implementation of scientific insights into the health care system. An important goal of the Summer School is the interaction between participants as well as speakers, coming from both preclinical laboratories and clinical centers worldwide. We aim at stimulating interactions to foster multidisciplinary collaborations at an international level. Participants have the opportunity to present their research projects and data in oral or poster presentations.
Main topics for the Summer School

Confirmed Speakers
Location
For one week, participants will stay at the beautiful PortoBay Falésia, in the Algarve, Portugal. This will provide a unique opportunity to work closely with the experts, meet new people in the field and interact to foster multidisciplinary collaborations at an international level. Participants have the opportunity to present their research projects and data in oral or poster presentations.
Join us to improve your skills and broaden your network!

VENUE
Hotel PortoBay Falésia
Quinta do Milharó, Olhos de Água
8200-591 Albufeira – Portugal
WHAT OUR PARTICIPANTS SAY
WHAT OUR PARTICIPANTS SAY
Prince A., India: “The heterogeneity of the crowd is really where you get to know more and more people from different parts of the world, and what they are doing in the clinical setting, as well as in the labs. Different activities – just like a walk on a beach or soccer on a beach helps you to get to know more and more people and it helps you to mingle with the people of your own research interest.“
Tania C., Germany: “What I enjoyed most so far is really that you interact with many different people from different disciplines and also different career levels. You can actually get a lot of inspiration on your own projects.“
Gunn A., Denmark: “I would like to say thank you for an absolute fantastic week in Portugal! I have never experienced a more successful event, both socially and professionally!”
Rihan E. B., Italy: “Especially in this very challenging war against cancer, we really need to stand together, because the whole is greater than the sum of its parts, so we need to be a core against cancer. And this is definitely what I found here in Cancer Core Europe.“
Omnia E., Egypt: “I like the diversity here, and the creativity, and how everyone gets to interact based on his own background.“
Andreas M., Germany: “Summer School brings people together, it creates opportunity, it gives us an important stimulus, and really fosters collaboration between young researchers.“
SCIENTIFIC COMMITTEE
SCIENTIFIC COMMITTEE

Dr. Nick Tobin
Karolinska Institutet (KI)
Stockholm, Sweden

Dr. Irene Braña
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Dr. Richard Baird
Cancer Research UK Cambridge Centre
Cambridge, United Kingdom

Prof. Svetlana Bajalica Lagercrantz
Karolinska Institutet (KI)
Stockholm, Sweden

Prof. Ingemar Ernberg
Karolinska Institutet (KI)
Stockholm, Sweden

Dr. Marleen Kok
The Netherlands Cancer Institute (NKI)
Amsterdam, The Netherlands

Prof. Stefan Fröhling,
National Center for Tumor Diseases (NCT) – DKFZ
Heidelberg, Germany

Dr. Priya Chudasama,
National Center for Tumor Diseases (NCT) – DKFZ
Heidelberg, Germany

Dr. Delia Mezzanzanica,
Istituto Nazionale dei Tumori di Milano (INT)
Milan, Italy

Dr. Thomas Mercher,
Institut Gustave Roussy (IGR)
Villejuif, France

Dr. Mate Maus
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
ORGANISERS
ORGANISERS
SUPPORTERS
The German Cancer Consortium (DKTK) is a long-term, joint initiative involving the German Federal Ministry of Education and Research (BMBF), participating German states and the German Cancer Research Center (DKFZ) and was established as one of six German Health Research Centres (DZGs) in 2012. The German Cancer Research Center, the consortium’s core center, works together with more than 20 academic research institutions and university hospitals in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Munich and Tübingen to create the best possible conditions for preclinical-translational cancer research. The consortium promotes interdisciplinary research at the interface between basic research and clinical research. Another key focus of the consortium’s work is on developing research platforms to speed up the application of personalized cancer treatments and to improve the diagnosis and prevention of cancer.
The mission of Cancer Prevention Europe (CPE), a consortium of organizations across the whole of Europe, is to reduce morbidity and mortality from cancer in European populations through prevention and earlier detection of the disease. This will be accomplished through (1) research to optimize the implementation of known preventive strategies, (2) the dissemination of established best practices in prevention, in order to see innovative research translated into effective cancer prevention guidelines and policies nationally and internationally, and (3) research to identify novel targets for prevention.
Molecular Oncology is an open access journal owned by FEBS. The journal considers Research Articles from the fields of basic, translational, and clinical cancer research. We also publish Review Articles, Commentaries and Policy Papers discussing emerging concepts in cancer research, cancer diagnosis, prevention and care. Journal profits are re-invested in the scientific community. Manuscripts are handled by a team of dedicated academic Section Editors under a transparent peer review scheme.
Algarve Biomedical Center has as its main mission the creation, transmission and dissemination of a culture of research and development, helping the training of highly qualified and differentiated professionals. ABC’s vision is to be a center of excellence dedicated to development, training and research, based on the pillars of efficiency, quality, competitiveness and innovation.
EMBO is an organization of more than 2,000 leading researchers that promotes excellence in the life sciences in Europe and beyond. The major goals of the organization are to support talented researchers at all stages of their careers, stimulate the exchange of scientific information, and help build a research environment where scientists can achieve their best work.
NOVARTIS is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.
ORGANISING TEAM

Petra Oberrauch,
National Center for Tumor Diseases (NCT) – DKFZ
Heidelberg, Germany

Thomas Guegan,
VHIO Academy (VHIO)
Barcelona, Spain
(on parental leave)

Natalia Molner,
VHIO Academy (VHIO)
Barcelona, Spain

Giovanni Scoazec,
Istituto Nazionale dei Tumori di Milano (INT)
Milan, Italy